

In re Application of: Stephen J. VESPER
 Serial No.: 09/866,793
 Filed: May 30, 2001
 For: METHODS FOR ISOLATING...



Art Unit: 1635
 Confirmation No.: 5682
 Examiner: SHAHANA-SHAH
 Washington, D.C.
 Atty.'s Docket: VESPER1
 Date: January 11, 2002

Handwritten: G.A.H./1635
 RECEIVED
 JAN 18 2002
 TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231
 Sir:

Transmitted herewith is an [XX] Amendment []
 in the above-identified application.

- [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- [] No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)	Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra	Rate	Additional Fee	Rate	Additional Fee
Total	6	Minus	20		0	x 9	\$	x18	\$
Indep.	2	Minus	3		0	x42	\$	x84	\$
First Presentation of Multiple Dependent Claim						140	\$	+280	\$
TOTAL ADDITIONAL CLAIMS FEE							\$	Total	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 - ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 - *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
- The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

- [XX] Conditional Petition for Extension of Time
 If any extension of time for a response is required applicant requests that this be considered a petition therefor.
- [XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity Response Filed Within	Other Than Small Entity Response Filed Within
[] First - \$ 55.00	[XX] First - \$ 110.00
[] Second - \$200.00	[] Second - \$ 400.00
[] Third - \$460.00	[] Third - \$ 920.00
[] Fourth - \$720.00	[] Fourth - \$1440.00
- [] Less fees (\$) already paid for months extension of time on .

- [] Please charge my Deposit Account No. 02-4035 in the amount of \$_____ . A duplicate copy of this sheet is attached.
- [] A check in the amount of \$_____ is attached (check no. _____).
- [XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ 110.00 is attached.
- [XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:
 Anne M. Kornbau
 Registration No. 25,884

AMK:rmp
 F:\Epa\Vesper1\Pro\cov2.vpd

01/16/2002 KSEBREM1 00000023 09866793

01 FC:115 110.00 0P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: VESPER1

#7
Curtis
1/24/02

In re Application of:

) Art Unit: 1645

S.J. VESPER

) Examiner: SHAHNAN-SHAH

Serial No.: 09/866,793

) Confirmation No. 5682

Filed: May 30, 2001

) Washington D.C.

For: METHODS FOR ISOLATING
AND USING FUNGAL
HEMOLYSINS

) January 11, 2002



RECEIVED
JAN 18 2002
TECH CENTER 1600/2900

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action of
September 13, 2001, for which a one month extension of
time to respond is hereby requested, please enter the
following amendment:

IN THE SPECIFICATION

Page 7, please amend paragraph [0028] as
follows:

[0028] The hemolysin protein as obtained above was
conjugated to KLH (key hole limpet hemocyanin) as a
carrier, using glutaraldehyde chemistry, linking amines
of the protein and the carrier. This preparation was
injected into animals as an immunogen. However, fungal
hemolysins proteins need not be conjugated for use in a
vaccine.

al